摘要
目的:观察全反式维甲酸、α干扰素联合小剂量阿糖胞苷治疗低增生性急性髓性白血病(acute myeloid leukemia,AML)的临床疗效。方法:回顾性收集2018年2月至2021年2月遂宁市中心医院诊治的低增生性AML患者的临床资料,共76例。根据患者自愿选择的治疗方法不同分为对照组与治疗组,对照组34例,予以小剂量阿糖胞苷治疗;治疗组42例,在对照组基础上予以全反式维甲酸、α干扰素治疗。比较两组临床疗效、不良反应及随访6个月生存情况,并观察治疗前后血清碱性成纤维细胞生长因子(basic fibroblast growth factor,bFGF)、转化生长因子(transforming growth factorβ1,TGF-β1)、血管内皮生长因子(vascular endothelial growth factor,VEGF)表达情况。结果:治疗组患者临床治疗有效率为73.81%,高于对照组的50.00%(P<0.05)。与治疗前相比,两组患者治疗后血清bFGF、VEGF表达均明显降低,TGF-β1表达明显升高,且治疗组bFGF、VEGF表达均明显低于对照组,TGF-β1表达明显高于对照组(均P<0.05)。治疗组中位生存时间为16.3个月,对照组中位生存时间为7.8个月,两组患者生存分析差异无统计学意义(P>0.05)。治疗组患者30 d病死率明显低于对照组(P<0.05),两组患者6个月生存率比较差异无统计学意义(P>0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:全反式维甲酸、α干扰素联合小剂量阿糖胞苷治疗低增生性AML疗效确切,能调节患者血清bFGF、TGF-β1及VEGF表达,改善近期预后,安全性好。
Objective:To study the clinical effect of all-trans retinoic acid and interferon-αcombined with low-dose cytarabine in the treatment of hypoproliferative acute myeloid leukemia(AML).Methods:The clinical data of 76 patients with hypoproliferative AML diagnosed and treated in the Suining Central Hospital from February 2018 to February 2021 was retrospectively analyzed.The patients were divided into a control group(34 cases)and a treatment group(42 cases)according to the treatment method.Patients in the control group were treated with low-dose cytarabine,while those in the observation group were treated with all-trans retinoic acid and interferon-αcombined with low-dose cytarabine.The clinical effect,adverse reactions,and 6-month survival were compared between the 2 groups.The expression of serum basic fibroblast growth factor(bFGF),transforming growth factorβ1(TGF-β1),and vascular endothelial growth factor(VEGF)was observed.Results:The clinical treatment effective rate in the treatment group(73.81%)was higher than that in the control group(50.00%)(P<0.05).A?ter the treatment,the expression of serum bFGF and VEGF significantly decreased,and the expression of TGF-β1 significantly increased in the 2 groups.The expression of bFGF and VEGF in the treatment group was significantly lower than that in the control group,and the expression of TGF-β1 was significantly higher than that in the control group(all P<0.05).The median survival time was 16.3 months in the treatment group and 7.8 months in the control group.There was no significant difference between the 2 groups(P>0.05).The 30 d mortality rate in the treatment group was significantly lower than that in the control group(P<0.05),but there was no significant difference in 6-month survival rate between the 2 groups(P>0.05).There was no significant difference in the incidence of adverse reactions between the 2 groups(P>0.05).Conclusion:All-trans retinoic acid and interferon-αcombined with low-dose cytarabine is effective in the treatment of hypoproliferative AML,w
作者
李艳秋
丁超
LI Yanqiu;DING Chao(Department of Hematology,Suining Central Hospital,Suining Sichuan 629000,China)
出处
《临床与病理杂志》
CAS
2022年第12期2897-2904,共8页
Journal of Clinical and Pathological Research
基金
四川省卫生和计划生育委员会科研课题(17PJ432)。
关键词
低增生性急性髓性白血病
全反式维甲酸
Α干扰素
阿糖胞苷
疗效
hypoproliferative acute myeloid leukemia
all-trans retinoic acid
interferon-α
cytarabine
curative effect
